Navigation Links
Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
Date:5/6/2009

>)

Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics for major unmet medical needs. Aegera has three programs in clinical development. In addition to AEG33773, Aegera is developing

    - AEG35156 targets the key anti-apoptotic protein XIAP, and is in
      multiple randomized Phase II clinical trials;
    - HGS1029(AEG40826) is a small molecule pan-IAP inhibitor in Phase 1
      development. It has demonstrated very promising preclinical activity
      and is partnered with Human Genome Sciences, Inc. (Nasdaq:  HGSI) for o
      ncology in all countries except Japan.

'/>"/>
SOURCE AEGERA THERAPEUTICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
2. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
3. Aegera Therapeutics welcomes two experienced executives to its board of directors
4. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
5. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
6. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
9. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... Kjell Lindgren , who is making final preparations for ... International Space Station , will be available for live ... 7. Lindgren will participate from the Gagarin Cosmonaut ... The interviews will be preceded at 7:30 a.m. by a ... To schedule an interview, media must contact Stephanie Stoll ...
(Date:6/30/2015)... NEW YORK , June 30, 2015  Today, Americord ... the U.S., announced Andrew Horne , a partner at ... Advisory Board. Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   ... appointment to Americord,s Advisory Board," says Martin Smithmyer , ... experience in his legal career that will assist Americord,s growth ...
(Date:6/30/2015)... Kent, WA (PRWEB) , ... June 30, 2015 ... ... offers a hydrophilic filter that does not sacrifice selectivity to achieve faster flow ... construction combines extremely fine pores with significant open space to allow easy liquid ...
(Date:6/30/2015)... ... June 30, 2015 , ... The maximum number of shares ... outstanding common shares (including shares of unvested restricted stock). On June 29, 2015, the ... price of Cryo-Cell’s shares reported on the OTCBB was $2.29 per share. , The ...
Breaking Biology Technology:NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2Americord Registry Announces Andrew Horne as Advisory Board Member 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3
... to testing for sleep-related illnesses , , SAN ... of in-home sleep testing and Continuous Positive Airway Pressure ... of the nation,s largest healthcare benefit providers. As a ... able to serve more patients with sleep-related illnesses such ...
... June 16 Strativa Pharmaceuticals, the proprietary products division ... Inc. (NYSE: PRX ), today announced that ... Drug Application (NDA) to the Food and Drug Administration ... buccal tablets, as planned. If approved, Strativa could ...
... , , Harness the Dual Benefits of Freshly ... CHICAGO, June 16 In today,s competitive environment and economic ... a promising new drug compound or chemical entity cannot be ... to do more with less, and productivity and cost savings ...
Cached Biology Technology:SleepQuest Signs National Contract With Aetna 2Strativa's Development Partner, BioAlliance Pharma, Submits Loramyc(R) NDA 2Celsis Outlines the Top Five Advantages of Cryo-plateable Hepatocytes 2Celsis Outlines the Top Five Advantages of Cryo-plateable Hepatocytes 3Celsis Outlines the Top Five Advantages of Cryo-plateable Hepatocytes 4
(Date:6/16/2015)... Fingerprint Cards (FPC) raises the revenue guidance for ... at least 340 MSEK to that it will amount to ... growth and orders received the revenue guidance for 2015 is ... will exceed 1,500 MSEK to an updated guidance that revenue ... Due to receipt of orders of touch fingerprint sensors with ...
(Date:6/12/2015)... , June 12, 2015  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... its patent to electronically capture, analyze and identify ... facial recognition methods. This system can: ... by an enrollment and subsequent sign-on process is ...
(Date:6/9/2015)... 09, 2015 Research and Markets  ( ... "Gesture Recognition & Touchless Sensing Market by ... & Others), Product (Biometric & Sanitary Equipment) & ... report to their offering. The total ... to reach $ 23.55 Billion by 2020 at ...
Breaking Biology News(10 mins):Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2
... forest cover in the eastern United States in recent decades ... analysis published in the April 2010 issue of BioScience ... A. Drummond and Thomas R. Loveland of the US Geological ... were cleared for agriculture on a large scale, but from ...
... Four billion years ago, our then stripling sun radiated only 70 ... things on Earth being equal, with so little energy reaching the ... But ancient rocks hold ample evidence that the early Earth was ... something must have compensated for the reduced solar output and kept ...
... DURHAM, N.C. The number of sea turtles inadvertently ... years may reach into the millions, according to the ... from gillnet, trawl and longline fisheries worldwide. The ... journal Conservation Letters , analyzed data compiled ...
Cached Biology News:Early Earth absorbed more sunlight -- no extreme greenhouse needed to keep water wet 2Early Earth absorbed more sunlight -- no extreme greenhouse needed to keep water wet 3Early Earth absorbed more sunlight -- no extreme greenhouse needed to keep water wet 4Commercial fishing estimated to kill millions of sea turtles 2Commercial fishing estimated to kill millions of sea turtles 3
Mouse monoclonal antibody raised against a partial recombinant ACTN4. NCBI Entrez Gene ID = ACTN4...
Rabbit polyclonal antibody to GluR2...
... can be used to test the crossreactivity ... sera that are commonly used as blocking ... spots for 19 different protein preparations on ... crossreactivity and species specificity, QC of purified ...
... array sample elements. , ,Includes: , DiscoverLight ... BSA in PBS (10X): 50 ml , ... , BupH Phosphate Buffered Saline: 8 packs ... ml ampules , SuperSignal West Pico Luminol Enhancer: 2 ...
Biology Products: